Sygnomics lands $2 million grant to advance personalized precision oncology solutions.
The Andy Hill Cancer Research Endowment (CARE) Fund awarded a $2 million Life Science
SYGNAL used to characterize treatment-induced evolution of tumor cell states in a single patient
Glioblastoma (GBM) is a heterogeneous tumor made up of cell states that evolve over
Sygnomics and xCures present at 2021 SNO Annual Meeting
Sygnomics in collaboration with xCures presented a poster at 2021 SNO Annual Meeting to
Sygnomics partners with slalom_build to develop a functional prototype of a web-based Precision Oncology platform
Sygnomics partnered with leading global business and technology consulting company, Slalom to provide an
A technology to generate a patient-specific disease-relevance network map
The 75 percent failure rate of cancer therapies underscores the need for personalized treatments.
ISB researchers develop first systems scale predictive model for glioblastoma
In a study published (online in advance) in Cell Systems on July 14, 2016, researchers at